{"id":608,"date":"2026-07-31T11:01:03","date_gmt":"2026-07-31T09:01:03","guid":{"rendered":"https:\/\/spidersex.blog\/cos-e-il-calo-della-libido\/"},"modified":"2026-07-31T11:01:03","modified_gmt":"2026-07-31T09:01:03","slug":"cos-e-il-calo-della-libido","status":"publish","type":"post","link":"https:\/\/spidersex.blog\/en\/what-is-low-libido\/","title":{"rendered":"What Is the Decline in Libido"},"content":{"rendered":"

She says she doesn't feel anything anymore. He says he doesn't understand what's happened to him.<\/p>\n

Two similar sentences, two different bodies, and yet the clinic of desire found itself observing them through separate lenses for years. Then something changed. Not entirely, not yet, but what emerged in the 2026 trials adds a couple of pieces to the map. Pieces that, honestly, some would have liked to see sooner.<\/p>\n

Libido<\/strong> Insufficient libido, hypoactive sexual desire, hypoactive sexual desire disorder: the labels change, the knot remains. We're talking about a marked absence of erotic thoughts, fantasies, desire for contact that persists over time. Creating distress. It is not the physiological pause after bereavement or childbirth. It is a silence of the body that drags on and that many people experience as a betrayal.<\/p>\n

There's no need to accumulate frustration for months without understanding. Those who have dealt with it for years know it well: desire is not a switch. Sometimes biology takes its own path. And sometimes you can bring it back, at least in part, with tools that until yesterday seemed destined for others.<\/p>\n

Hormones and differences: why testosterone isn't just for men<\/h2>\n

Transdermal testosterone gel for women with low libido is not an absolute novelty, but in 2026 the available data have a more decisive tone than a few years ago. A late-stage trial has gathered solid evidence on tolerability. Participants who used the gel reported a measurable increase in desire. Researchers speak of an acceptable safety profile in the short term.<\/p>\n

That's no small thing.<\/p>\n

Of course, important gaps remain. The long-term effects on cardiovascular health and breast cancer risk are not yet extensively documented. That means a few pieces are still missing to understand whether and how much it is worth using beyond the standard study months. In the meantime, though, the gel works. And it works without producing the side effects feared by those who associate testosterone only with virilization.<\/p>\n

In the other half of the hormonal sky, the FDA has left a door ajar. April 2026: the agency invites manufacturers of already-approved testosterone replacement therapies to evaluate a new indication. Treating reduced libido in men with idiopathic hypogonadism, even when hormone levels do not plunge below the classic thresholds. This opens up an interesting niche, because it moves the bar from \u201clow hormone in a test tube\u201d to \u201clow desire in real life\u201d.<\/p>\n

It's a delicate step. Desire and Control<\/a> It is inevitably intertwined with biology, but cannot be reduced to it. The push to medicalize desire can become a dangerous shortcut if we forget how much relational context, chronic stress, sleep, and our self-image matter.<\/p>\n

Flibanserin in Men: A Dead End and the Questions It Leaves Behind<\/h2>\n

If testosterone acts on the circuits of sexual motivation, flibanserin works on brain neurotransmitters. Dopamine and norepinephrine up, serotonin down. Approved for years for premenopausal women, in 2026 comes news of a phase 2 study that aimed to test it in men. Sponsor: Mohit Khera. Subject: male hypoactive sexual desire disorder. Status: terminated.<\/p>\n

Terminated does not mean failed, but neither does it mean concluded with results to publish. The study stopped. We don't know why. It may be that recruitment was complicated, or that preliminary data did not justify the investment.<\/p>\n

Some turn up their noses, others shrug. Clinical research is also made of dead ends. But one detail remains that gives pause: when an effort is made to extend to people with penises a drug designed for people with vulvas, the industry's interest seems to deflate. Gender bias? Maybe. Or perhaps the market simply perceives a demand that is less strong, less organized, less able to make itself heard. Sexual Wellbeing<\/a> male is still a territory that struggles between stereotypes and embarrassment.<\/p>\n

And yet it would be enough to listen to those seeking help.<\/p>\n

Between consent, expectations, and chemical realism<\/h2>\n

Any therapy for desire imposes an uncomfortable question: for whom are we really raising libido? For the person who suffers, or for the partner who demands it? The question is not rhetorical. There is a line between restoring a lost dimension of pleasure and bowing to external pressures that make low desire look like a malfunction to be fixed quickly.<\/p>\n

A gel, a pill, a patch do not replace the work of a couple. They can be a crutch, a trigger, a way to reconnect with sensations that seemed switched off. But if the relational foundation is crumbling, no hormone will rebuild it. This is where Consent Dynamics<\/a> becomes crucial: consenting to a therapy that changes desire means being clear about what you are looking for. And what you are not.<\/p>\n

It is not so strange, after all, that many people prefer a combined approach. Sex therapy and, when needed, medication. A dual path, without magic wands.<\/p>\n

Sources and references<\/h2>\n

Sources:<\/strong><\/p>\n